Dr. M. Juliana McElrath

powered by
COS Expertise®
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Institute
Co-DirectorAppointed: 2007
Fred Hutchinson Cancer Research Center
Clinical Research Division
Infectious Diseases
MemberAppointed: 2001
University of Washington
School of Medicine
Medicine
Allergy and Infectious Diseases
ProfessorAppointed: 2001
Professional Headshot of M. Juliana McElrath

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N.
P.O. Box 19024
D3-100
Seattle, Washington 98109-1024
United States

Contact Information

Phone: (206) 667-6704
Fax: (206) 667-4411
jmcelrat@fhcrc.org

Qualifications

Ph.D., Medical University of South Carolina, 1980.
M.D., Medical University of South Carolina, 1978.

Expertise and Research Interests

Protection and Control of HIV-1 Infection by T Cell Immunity.

Our laboratory seeks to identify the components of immunity that are important in preventing and controlling HIV-1 infection. Our goal is to understand how T cell memory is induced both in natural infection and by immunization, and to identify the properties of T cells that confer containment or eradiation of HIV-1.
Our studies encompass a broad range of immunologic investigations in persons who experience unusual control of HIV-1 infection. These include individuals with newly diagnosed infection, those with long-term non-progressive disease who control infection for more than a decade without antiretroviral treatment, and individuals repeatedly exposed but not infected. These clinical cohorts have been assembled for longitudinal studies in both Seattle and in countries where the HIV epidemic is widespread (South Africa, Uganda). Most recent studies focus on African HIV discordant couples, providing a unique opportunity to address host characteristics that lead to altered susceptibility to infection and transmission. In addition, we have targeted studies to gain further understanding of how HIV-1 gains entry into the mucosa and the induction of HIV-specific mucosal immunity.
We also devote extensive efforts to HIV-1 vaccine development. First, we lead a large collaborative project to identify innate immune mechanisms that may enhance adaptive immunological memory to HIV. Further, our laboratory program oversees the evaluation of multiple candidate vaccines in a international vaccine network, which provides basic insights into how different vaccine modalities elicit optimal B- and T-cell immunity to HIV-1 that may be ultimately protective against infection and disease.

Keywords

COS Keywords:

AIDS, HIV, Infectious Diseases or Agents, Microbiology, Oncology.

Additional Terms:

AIDS Prevention, AIDS Treatment, Disease Manifestation, HIV/SIV Infection, Microbiology, Viral Disease, Viruses.

Memberships

American College of Physicians
Association of American Physicians
National Institute of Health AIDS Vaccine Research Subcommittee

Honors and Awards

2008, M. Juliana McElrath, American College of Physicians, Fellowship
2000-2006, M. Juliana McElrath, Burroughs Wellcome, Clinical Scientist Award in Translational Research
1997, M. Juliana McElrath, National Institutes of Health (NIH), National Institutes of Health (NIH), Merit Award
1994, M. Juliana McElrath, University of Washington (UW), Immunology Core, Associate Director
1993, M. Juliana McElrath, Collaborative Mucosal Immunity Group, Collaborative Project Coordinator

Publications

  • M.J. McElrath, S. C. DeRosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O.D. Defawe, D.K. Carter, J. Hural, R. Akondy, S.P. Buchbinder, M.N. Robertson, D.V. Mehrotra, S.G. Self, L.C. Corey, J.W. Shiver, D.R. Casimiro (2008) HIV Vaccine-induced Immunity in the Test-of-Concept Step Study., Lancet, 372 (9653), 1894-1905
  • F. Hladik, M.J. McElrath (2008) Setting the Stage: host invasion by HIV., Nat Rev Immunol., 8 (6), 447-457
  • J. Cao, J. McNevin, M. McSweyn, Y. Liu, J. I. Mullins, M. J. McElrath (2008) Novel cytotoxic T-lymphocyte escape mutation by a three-amino acid-insertion in the human immunodeficiency virus type 1 p6Pol and p6 Gag late domain associated with drug resistance., J Virol., 82 (1), 495-502
  • F. Hladik, P. Sakchalathorn, L. Ballweber, G. Lentz, M. Fialkow, D. Eschenbach, M.J. McElrath (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1., Immunity, 26 (2), 257-270
  • Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, Zhao LP, McElrath MJ (Mar 2006) Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection., Journal of virology, 80 (5), 2463-71 Abstract
  • H. Horton, I. Frank, R. Baydo, E. Jalbert, J. Penn, S. Wilson, J.P. McNevin, M.D. McSweyn, D. Lee, Y. Huang, S. D. DeRosa, M.J. McElrath (2006) Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection., J Immunol., 177 (10), 7406-7415
  • E.C. Speelmon, D. Livingston-Rosanoff, S.S. Li, Q. Vu, J. Bui, D.E. Geraghty, L.P. Zhao, M.J. McElrath (2006) Genetic association of the antiviral restriction factor TRIM5α with human immunodeficiency virus type 1 infection., J Virol., 80 (5), 2463-2471
  • J. Cao, J. McNevin, U. Malhotra, M.J. McElrath (2003) Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection., J Immunol., 171 (7), 3837-3846
  • T. Zhu, L. Corey, Y. Hwangbo, J.M. Lee, G.H. Learn, J.I. Mullins, M.J. McElrath (2003) Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals., J Virol., 77 (11), 6108-6116
  • U. Malhotra, S. Holte, S. Dutta, M.M. Berrey, E. Delpit, D.M. Koelle, A. Sette, L. Corey, M.J. McElrath (2001) Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment., J Clin Invest., 107 (4), 505-517
  • L. Musey, Y. Hu, L. Eckert, M. Christensen, T. Karchmer, M.J.McElrath (1997) HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women., J Exp Med., 185 (2), 293-303

Profile Details

Last Updated: 2/24/2009

COS Expertise ID #916665
Reference this profile directly: http://myprofile.cos.com/MCELRATH